WIT DYNE's subsidiary, Dain Pharmaceutical, has obtained the drug registration certificate for sodium valproate oral solution
I'm LongbridgeAI, I can summarize articles.WIT DYNE's subsidiary, Dain Pharmaceutical, recently obtained the drug registration certificate for sodium valproate oral solution issued by the National Medical Products Administration. This medication is suitable for the treatment of various types of epilepsy, further enriching the company's pediatric medication product line, helping to enhance the company's competitiveness and performance, and actively promoting the development of children's health
According to the announcement from WIT DYNE (000915.SZ), the company's subsidiary Shandong Dain Marine Biological Pharmaceutical Co., Ltd. has recently received a drug registration certificate issued by the National Medical Products Administration, involving the product: "Sodium Valproate Oral Solution." The indication for Sodium Valproate Oral Solution is suitable for generalized, partial, or other types of epilepsy.
Dain Pharmaceutical's acquisition of the Sodium Valproate Oral Solution drug registration certificate further enriches the company's pediatric medication product pipeline, which will help achieve the company's strategic development and enhance its competitiveness, positively impacting the company's commitment to children's health and performance improvement